Abstract 1141P
Background
Disruption of the homologous recombination repair (HRR) pathway was reported in at least half of high-grade serous ovarian cancer (HGSOC) patients. HRR deficiency (HRD) is associated with superior response to PARP inhibition maintenance therapy in both primary and relapsed HGSOC. Moreover, HRD is a prerequisite for combination therapy with Bevacizumab and Olaparib following first-line chemotherapy. Aim of this study was to evaluate if a machine learning framework trained on matrix-assisted laser desorption/ionization imaging mass spectroscopy (MALDI-IMS) data can accurately predict the HRD status in HGSOC tumors.
Methods
We collected during surgery paired formalin-fixed paraffin-embedded (FFPE) tumor samples from primary and at relapse in 50 HGSOC patients. HRD status was previously evaluated using the Myriad myChoice® CDx test, that was conclusive in 88 samples. HRD status served as the reference label for machine learning of MALDI-IMS data generated from the same samples.
Results
Models achieved a 96.8% mean accuracy and 0.995 mean area under the curve (AUC) on three randomized subsets of the data. Utilizing a majority vote scheme, all patients could be assigned the correct HRD status.
Conclusions
Using an accessible, cheaper and easy to reproduce method such as MALDI-IMS technology combined with a machine learning framework we reached a similar performance to the Myriad myChoice® CDx test in predicting HRD status in HGSOC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
NOGGO eV- North eastern Society for Gyencologic Oncology and the ENGOT Tumor Bank for Ovarian Cancer.
Funding
Has not received any funding.
Disclosure
M. Hummel: Financial Interests, Personal, Expert Testimony: AstraZeneca; Financial Interests, Personal, Expert Testimony: MSD; Financial Interests, Personal, Expert Testimony: Novartis; Financial Interests, Personal, Expert Testimony: Lilly; Financial Interests, Personal, Expert Testimony: Pierre Fabre. W. Weichert: Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: BMS; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Pfizer; Financial Interests, Personal, Advisory Board: Merck; Financial Interests, Personal, Advisory Board: Lilly; Financial Interests, Personal, Advisory Board: Boehringer; Financial Interests, Personal, Advisory Board: Novartis; Financial Interests, Personal, Advisory Board: Takeda; Financial Interests, Personal, Advisory Board: Bayer; Financial Interests, Personal, Advisory Board: Amgem; Financial Interests, Personal, Advisory Board: Astellas; Financial Interests, Personal, Advisory Board: Illumina; Financial Interests, Personal, Advisory Board: Siemens; Financial Interests, Personal, Advisory Board: Agilent; Financial Interests, Personal, Advisory Board: ADC; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: Molecular Health; Financial Interests, Institutional, Sponsor/Funding: Roche; Financial Interests, Institutional, Sponsor/Funding: MSD; Financial Interests, Institutional, Sponsor/Funding: BMS; Financial Interests, Institutional, Sponsor/Funding: AstraZeneca. E.I. Braicu: Financial Interests, Institutional, Sponsor/Funding: BMBF; Financial Interests, Institutional, Sponsor/Funding: AstraZeneca; Financial Interests, Institutional, Sponsor/Funding: Bayer; Financial Interests, Institutional, Sponsor/Funding: MolecularHealth; Financial Interests, Institutional, Sponsor/Funding: Roche; Financial Interests, Institutional, Sponsor/Funding: Diagnostics; Financial Interests, Institutional, Sponsor/Funding: Clovis; Financial Interests, Institutional, Sponsor/Funding: GSK; Financial Interests, Institutional, Sponsor/Funding: MSD; Financial Interests, Institutional, Sponsor/Funding: Tesaro; Financial Interests, Personal, Advisory Board: AbbVie; Financial Interests, Personal, Advisory Board: Amgen; Financial Interests, Personal, Advisory Board: AstraZeneca; Financial Interests, Personal, Advisory Board: Clovis; Financial Interests, Personal, Advisory Board: GSK; Financial Interests, Personal, Advisory Board: MSD; Financial Interests, Personal, Advisory Board: Roche; Financial Interests, Personal, Advisory Board: Tesaro; Financial Interests, Personal, Advisory Board: Seattle Genetics; Financial Interests, Personal, Advisory Board: MolecularHealth. All other authors have declared no conflicts of interest.